In conclusion, based on preclinical models of docetaxel resistance and primary docetaxel-naïve PCa patient samples, we propose a 6-molecule surface fingerprint composed of EpCAM, CD9, CD44, CD59, CD95, and SSEA-4 as a candidate set of surface antigens that may potentially predict the response to docetaxel in PCa patients before therapy. The gene discussed is EPCAM; the disease is posterior cortical atrophy.